BioNTech Investor Day Presentation Deck
●
●
BNT152 + BNT153
Increase CD8 proliferation and reduce Treg fraction
BNT152 (IL-7) is anticipated to potentiate the anti-tumor activity of BNT153 (IL-2) by:
Reduction/normalization of the BNT153-mediated increase in the Treg fraction among CD4+ T cells
Support of T cell lymphopoiesis and survival of memory T cells
●
BNT152
Stimulates recently activated anti-tumor
T cells and regulatory T cells
BNT153
mRNA encoding IL-7
Sensitizes T cells to IL2 & increases CD8+
and CD4+ T cell expansion and survival
Controls fraction of immunsuppressive Treg
among CD4+ T cells that are stimulated by IL-2
CD8+ T cell expansion of
BNT152+153 mainly driven by BNT152
Cells per μl blood
10000
7500-
5000-
2500-
0
CD8+ T cells
Control
****
BNT152
ns
****
H+..
BNT153
BNT152+153
Percent Treg of CD4
BNT152 normalizes the
Treg fraction elevated by BNT153
25-
20-
15-
Treg frequency
Control
ns
BNT152
****
ns
NUM
BNT153
BNT152+153
RiboCytokines
BIONTECH
145View entire presentation